EquityFlow › Companies › KINS

KINS

Biotech · Tokyo, JP

Comprehensive microbiome-care service for humans and pets; drug-discovery seeds.

Funding history

DateRoundAmount
Oct 2023Series B
KINS, a microbiome-care company, raised about JPY 1.5B in a second close of its Series B (including debt).
$10M

Investors

Dai-ichi LifeMizuho CapitalMoriroku HoldingsSMBC Venture Capital

Similar companies in Biotech

ImperagenHaga BiosciencePixelgen TechnologiesGallantChai DiscoverySNIPR BiomeCellbox LabsScope BiosciencesGenLuminaActitheraNUCLIDIUMAnocca
Explore funding flow on EquityFlow →